No structured organization for ovarian first line management emerges in France. Management across France seems to depend on regional contexts. Regions display no specific organization or delineate regional network for the ovarian cancer management or report centralized management revolving around referent centers. These different templates present a major problem in identifying differences, costs and benefit. To deal with this issue the Investigators propose a health economic evaluation based on cost-effectiveness analyses, completed with a budget impact analysis. This study will investigate the cost-effective management of patients with initial ovarian cancer using databases representative of different parts of French territories.
Study Type
OBSERVATIONAL
Enrollment
376
Calvados registry
Caen, France
Côte d'or registry
Dijon, France
Oveval
Lyon, France
Incremental cost-effectiveness ratio expressed in cost per relapse-free year gained
To perform a cost-effectiveness analysis in order to evaluate the most efficient organization for ovarian cancer in 1st line ot treatment
Time frame: 2 years after diagnosis
Incremental cost-effectiveness ratio expressed in cost per QALY(Quality-Adjusted Life Year) gained.
Time frame: 2 years after diagnosis
Budget impact analysis
Cost assessment performed retrospectively for each patient: hospital stays, visits and other health-related costs will be identified and measured based on the French national Health Insurance perspective. QALY (Quality-Adjusted Life Year)
Time frame: 2 years after diagnosis
Relapse-free survival (RFS)
Time frame: RFS will be assessed 2 years after diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.